Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Henry Ford Health System is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is split between 2 distinct examiners and 2 distinct art units, indicating a lack of concentration in the current workload. Such a distribution suggests that the applications in Biotechnology & Pharmaceuticals are diverse enough to be assigned to different specialized groups within the USPTO. Each of the 2 pending office actions is being handled in a separate administrative environment, which may lead to different prosecution timelines and requirements.
The examiner RODRIGUEZ, RAYNA B is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, each examiner is responsible for 1 pending office action. For practitioners, this means that the strategy for the health system must be tailored to 2 different individuals across 2 distinct art units. There is no single examiner or art unit that dominates the portfolio, requiring the legal team to monitor and respond to the specific nuances of each separate prosecution path for the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17746610 | COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIC PAIN AND SENSITIZATION OF TUMORS TO CHEMOTHERAPIES | BERTOGLIO, VALARIE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574776 | COMPOSITIONS COMPRISING ENDOSIDIN 2 FOR REDUCING SARS-COV-2 INFECTION | RODRIGUEZ, RAYNA B | — |
| 17746610 | COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIC PAIN AND SENSITIZATION OF TUMORS TO CHEMOTHERAPIES | BERTOGLIO, VALARIE E | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574776 | COMPOSITIONS COMPRISING ENDOSIDIN 2 FOR REDUCING SARS-COV-2 INFECTION | RODRIGUEZ, RAYNA B | 1628 | §102 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 17746610 | COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIC PAIN AND SENSITIZATION OF TUMORS TO CHEMOTHERAPIES | BERTOGLIO, VALARIE E | 1632 | §101§102§103 | Non-Final OA | — | Pending | May 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial